The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 10 May 2005, www.theannals.com, DOI 10.1345/aph.1E631.
 The Annals of Pharmacotherapy: Vol. 39, No. 6, pp. 1114-1118. DOI 10.1345/aph.1E631
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ng, C. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ng, C. V.

Hypersensitivity Reactions to Oxaliplatin in Two Asian Patients

Christina VT Ng, MBBS FRACP

Consultant Medical Oncologist, Department of Medicine, Division of Medical Oncology, University Malaya Medical Center, Jalan Universiti, Lembah Pantai 59100, Kuala Lumpur, Malaysia, fax 603/778-42169, christina{at}ummc.edu.my

Reprints: Dr. Ng

OBJECTIVE: To report 2 cases of hypersensitivity reactions associated with oxaliplatin treatment in Asian patients.

CASE SUMMARIES: A 33-year-old Chinese woman received adjuvant oxaliplatin in combination with fluorouracil and leucovorin. Shortly during her sixth infusion, she developed a severe hypersensitivity reaction. Despite prophylactic measures, she developed another reaction of similar severity during her subsequent infusion and was not further rechallenged with oxaliplatin. The second case involved a 45-year-old Malay woman who received oxaliplatin, fluorouracil, and leucovorin for metastatic colorectal cancer. Shortly during her ninth infusion, she developed a mild hypersensitivity reaction. With prophylactic measures, she developed less marked reactions with her subsequent 3 infusions.

DISCUSSION: Hypersensitivity reactions to oxaliplatin have been reported to be between 12% and 16% in the Western population. As of April 20, 2005, there are only 2 previously published reports of hypersensitivity reactions to oxaliplatin in 6 Asian patients. The incidence rates of such reactions in different Asian ethnic groups could vary. The cumulative dose, time of exposure to oxaliplatin, and clinical features were variable and unpredictable in all of the reported Asian patients who developed hypersensitivity reactions. An objective causality assessment using the Naranjo probability scale revealed that oxaliplatin was the highly probable cause of hypersensitivity in the 2 Asian patients reported by our center.

CONCLUSIONS: Patients who develop mild to moderate reactions can be rechallenged with the drug administered as a slow infusion with prophylactic measures. Desensitization may allow patients who experience severe hypersensitivity reactions to oxaliplatin to further receive effective therapy for their colorectal cancer.

Key Words: Asian ethnicity, oxaliplatin hypersensitivity

Published Online, May 10, 2005. www.theannals.com, DOI 10.1345/aph.1E631




homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.